The efficacy of monosialoganglioside GM1 treatment was evaluated in a
model of experimental stroke. Cerebral ischemia was induced by permane
nt occlusion of left middle cerebral artery. GM1 was administered intr
avenously soon after the occlusion of the artery and then intramuscula
rly daily for 7 days. Results indicate that GM1 can reduce the extent
of infarct volume and neurochemical deficits associated with the ische
mic event. The protection was more evident in the cortex than in the c
audate-putamen. These observations confirm and extend the evidence of
the GM1 efficacy in experimental models of stroke and further support
the usefulness of gangliosides in the treatment of these pathologies.
(C) 1994 Academic Press, Inc.